NIB shares rise as top broker calls the stock a buy

Is this stock a healthy opportunity?

The NIB Holdings Limited (ASX: NHF) share price is up 0.5% amid a leading expert's rating change on the ASX healthcare share. This coincides with the S&P/ASX 200 Index (ASX: XJO) rising by 0.6%, so the stock is not outperforming.

As we can see on the chart above, NIB shares are down by 7% in the last month. This sizeable decline in a relatively short amount of time has led one expert to think that the NIB share price is now good value.

Let's have a look at how much upside broker Morgans thinks the ASX healthcare share has.

ASX share price movement represented by doctor pressing digitised screen with array of icons including one entitled health insurance,

Image source: Getty Images

Buy rating on NIB shares

According to reporting by The Australian, Morgans Financial has decided to change its rating to add on NIB shares.

A price target on a business tells us where the broker thinks the share price will be in 12 months. Analysts don't have a crystal ball, but it's just their best guess about where the valuation will go. If they're correct, some price targets can imply large shareholder gains.

As reported by The Australian, the price target on the ASX healthcare share is $7.92. That suggests a possible rise of 13%. Combine that with the potential dividends over the next 12 months, and we're looking at a possible mid-to-high-teen return from NIB shares.

What has happened in recent times for the ASX healthcare share?

The company's last price-sensitive announcement was in March 2024. It revealed that its health insurance premiums would increase by an average of 4.1%. Its previous two increases, in 2023 and 2024, were the two lowest increases of the past 20 years.

At the time, NIB acknowledged that many household budgets were strained, but spending was growing across healthcare, driven by "an ageing population, the rise of chronic conditions and the cost of new technologies."

NIB's management noted that it aspires to be a health management and health insurance company.

The company also recently presented at the Macquarie conference in May. In that presentation, it showed that its revenue had grown every single year since FY05 and its underlying operating profit has been growing over the long term as well, aside from the COVID-hit years.

One of NIB's successes in recent years has been expanding into adjacent markets such as New Zealand, international workers and students, travel insurance, disability 'navigation', and more. The business has also been growing its market share in the core Australian private health insurance market.

NIB aims to become the disability sector's leading navigator by supporting NDIS participants and others with identified disabilities. It aims to reach around 50,000 participants by the end of FY25.

Outlook for NIB shares

In FY24, the business is expecting to achieve net policyholder growth of between 3% and 4% while maintaining stable underlying margins, before gradually returning to the target of between 6% and 7%.

Morgans seems confident on the company's outlook.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group and NIB Holdings. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Senior man looking at his laptop and pondering something.
Healthcare Shares

Could Mesoblast shares rise over 100% in 12 months?

Bell Potter has given its view on this stock.

Read more »

Two scientists analysing results on a computer screen.
Healthcare Shares

$10,000 invested in Pro Medicus and CSL shares 3 years ago is now worth…

Was I better off investing $10,000 into Pro Medicus or CSL shares three years ago?

Read more »

A share market investment manager monitors share price movements on his mobile phone and laptop
Healthcare Shares

Fund managers are loading up on CSL shares. Here's why

CSL is attracting renewed interest from fundies.

Read more »

Happy businessman fist pumping while looking at a tablet.
Healthcare Shares

Mesoblast wins FDA nod for new Ryoncil potency test

Mesoblast gets FDA approval for a new Ryoncil potency assay, aiming to ensure quality and support product expansion.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces.
Healthcare Shares

Can CSL shares hit $200? 3 things that need to go right

CSL needs to prove its earnings engine is accelerating again, not merely stabilising.

Read more »

Group of doctors celebrate by pumping fists in the air.
Healthcare Shares

Telix Pharmaceuticals vs Ramsay Healthcare: Which ASX healthcare stock made investors richer in 2026?

And find out which has the strongest upside ahead.

Read more »

Buy and sell written on red dice on top of stock market charts.
Broker Notes

Up 98%: Are CSL shares now a buy, hold or sell?

A leading expert provides his forecast for CSL’s rocketing shares.

Read more »

Doctor with stethoscope using a tablet in a hospital.
Broker Notes

What is this broker's view on Telix shares after yesterday's crash?

Here is the latest outlook from Bell Potter.

Read more »